← All thesesSLSNeutralLow convictionTuesday 17 November 2026עברית

SELLAS Life Sciences Group

This is the archived full research. Read the story

A small New York drug developer with no sales, waiting on one survival trial in a deadly blood cancer, priced as though the trial has already worked.

Our viewNeutral Low conviction
The scores
The profile · 1-4
Growthn/a →

No product is on sale, so there is no revenue to grow; the case is a trial result, not a growth rate.

Business quality2/4 →

No moat until approval; if approved, the first second-remission drug with orphan and biologic exclusivity, but venetoclax and transplant remain.

Financial position3/4 ↑

$134.7M of cash, no debt and about $30M a year of cash used fund years of trials, though not a launch.

Execution record2/4 →

REGAL enrolled and reached its count, but ten months after the registered date, and the China arbitration was lost.

Per share capture1/4 ↓

Shares nearly tripled in under two years through warrants, and a launch will need more; royalties go to MSK.

Potential2/4 →

About 8,750 patients a year by the company's count, worth perhaps $1.1B at Onureg's price, but only if REGAL succeeds.

Risk profile2/4 →

Binary: one trial result decides most of the value, and the cash would survive a failure.

Valuation2/4 ↑

At 11.6 times book value (what it owns minus what it owes), the price pays $1.39B for unproven drugs.

Evidence quality2/4 →

The filings and registry are solid, but GPS's efficacy rests on ten patients and single-arm studies, with no call to question management.

The bet · 2-3 years
Priced for success0.6×

If it works 0.6× · if it fails you keep about 5%.

The Verdict

We rate SELLAS Life Sciences Neutral, with low conviction. The business is weak today: it sells nothing, it has nearly tripled its share count in two years, and its lead drug's evidence rests on ten patients and studies without a fair comparison group. The price is full: the shares cost about $1.39B more than the cash, which already pays for a successful trial. The bet is priced for success: if the trial works, an approved drug at a sensible price adds little to today's value, and if it fails holders keep only about a twentieth. The result is due this month, so the view can change quickly.

The long caseIf REGAL shows patients live longer, GPS becomes the first drug to keep AML in a second remission, protected for years.

How we weighed it

The price against our value

Against it

No fair value is drawn because there are no sales; the price pays well above the cash for drugs not yet shown to work.

The business

Against it

Weak

Nothing is approved and the company has never sold a product; a moat appears only after a positive trial and approval.

Growth against what the price assumes

Cuts both ways

An approved GPS could reach thousands of patients a year with nothing else approved in its setting, but no sales exist today.

What could go wrong

Against it

One open-label trial decides most of the value, the earlier evidence is small, and new shares will be needed to launch.

Against competitors

Cuts both ways

No approved drug keeps a second remission, but doctors already continue venetoclax and azacitidine and send fit patients to transplant.

How its group is behaving

Cuts both ways

Small biotech shares move on their own trial news; the group's mood matters less than the readout.

The latest news and report

Cuts both ways

The final count was reached and the result promised this month, but it arrived late and the shares fell on it.

The evidence under this - 6 claims
C13inferencehigh confidence
At $7.47 the 203.9M shares are worth about $1,523M, 11.6 times book value of $131.8M, so the price pays about $1.39B above the cash for two unproven drugs.
derivedC12 gives the close, C10 the share count and C07 the cash; book value is the 10-Q's stockholders' equity, nearly all of it cash.
against this

SLS009 has its own value apart from GPS, so not all of the $1.39B is a bet on REGAL.

current state · 2026-11-16written 2026-11-17
C06facthigh confidence
GPS's case rests on a 10-patient Phase 2 trial at Moffitt in second remission: median survival of 21.0 months against 5.4 months in 15 patients treated at the same centre but not randomised.
against this

The comparison was not randomised and the GPS group was ten patients, so patients well enough to take a vaccine could simply have been healthier.

historical · Phase 2, final data at 30.8 months' follow-upwritten 2026-11-17
C07facthigh confidence
Cash and cash equivalents were $134.7M on 30 September 2026, against $71.8M at the end of 2025, with $9.3M of total liabilities and no debt.
current state · 2026-09-30written 2026-11-17
C02facthigh confidence
REGAL is a 1:1 randomised, open-label Phase 3 trial of GPS against investigators' choice of best available treatment in AML patients in second complete remission who cannot have a transplant; the primary endpoint is overall survival.
current state · 2026-10-28written 2026-11-17
C05management claimhigh confidence
SELLAS says it will report REGAL's topline primary endpoint result in November 2026.
against this

The 28 October release promised the result 'this quarter', which runs to the end of December.

forwardwritten 2026-11-17
C10facthigh confidence
Shares outstanding rose from 74.0M at the end of 2024 to 153.1M at the end of 2025 and 203.9M on 11 November 2026; $85.1M came in 2026 from 50.4M warrants exercised at an average $1.69.
historical · December 2024 to November 2026written 2026-11-17
01

The company

SELLAS is a 13-person company in New York that develops cancer drugs and pays others to run its trials and make them. GPS, licensed from Memorial Sloan Kettering Cancer Center, is its lead. The second, SLS009, licensed from China's GenFleet, is a drug given by drip alongside standard leukemia drugs.

Its future customers would be leukemia doctors and the insurers who pay them. Today it has none, because nothing is approved.

The evidence under this - 4 claims
C01facthigh confidence
SELLAS has no product on sale and two drug candidates: galinpepimut-S (GPS), a peptide immunotherapy against the WT1 protein licensed from Memorial Sloan Kettering, and SLS009 (tambiciclib), a CDK9 inhibitor licensed from GenFleet.
current state · 2026-09-30written 2026-11-17
C02facthigh confidence
REGAL is a 1:1 randomised, open-label Phase 3 trial of GPS against investigators' choice of best available treatment in AML patients in second complete remission who cannot have a transplant; the primary endpoint is overall survival.
current state · 2026-10-28written 2026-11-17
C06facthigh confidence
GPS's case rests on a 10-patient Phase 2 trial at Moffitt in second remission: median survival of 21.0 months against 5.4 months in 15 patients treated at the same centre but not randomised.
against this

The comparison was not randomised and the GPS group was ten patients, so patients well enough to take a vaccine could simply have been healthier.

historical · Phase 2, final data at 30.8 months' follow-upwritten 2026-11-17
C22facthigh confidence
GPS holds FDA orphan drug and Fast Track designations in AML; as a biologic filed under a licence application it would carry 12 years of US data exclusivity, while some GPS peptide patents expire in 2026 and others in 2033 to 2035.
against this

The patent covering the WT1-A1 peptide and some method-of-use patents expire in 2026, so exclusivity would rest on regulation more than on patents.

current state · 2026-03-19written 2026-11-17

How it makes money

It does not make money yet. It earns only interest on its cash and spends about $30M a year on trials and staff, paid for by selling shares. If GPS is approved, SELLAS would sell it in the US and Europe and pay a royalty of a few percent to Memorial Sloan Kettering; a Chinese partner holds the rights in Greater China.

The evidence under this - 3 claims
C01facthigh confidence
SELLAS has no product on sale and two drug candidates: galinpepimut-S (GPS), a peptide immunotherapy against the WT1 protein licensed from Memorial Sloan Kettering, and SLS009 (tambiciclib), a CDK9 inhibitor licensed from GenFleet.
current state · 2026-09-30written 2026-11-17
C07facthigh confidence
Cash and cash equivalents were $134.7M on 30 September 2026, against $71.8M at the end of 2025, with $9.3M of total liabilities and no debt.
current state · 2026-09-30written 2026-11-17
C08facthigh confidence
Operations used $22.4M of cash in the nine months to September 2026; the quarter's net loss was $10.1M, with research costs up 67% to $7.0M as the company prepares a licence application.
historical · nine months to 2026-09-30written 2026-11-17
Where the money comes from, stream by stream
StreamShare of sales (nine months to September 2026)How it earns it
None0%SELLAS has no product on sale; its only income is interest on its cash.

Who runs it

Angelos Stergiou, a doctor, founded the company in 2012 and has run it since; he was paid a $676,000 salary and a $390,390 bonus in 2025, the bonus tied to clinical and funding goals. Officers and directors together own about 1.3% of the shares.

The evidence under this - 2 claims
C27facthigh confidence
Angelos Stergiou founded the company in 2012 and has been chief executive since the 2017 merger with Galena; he was paid a $676,000 salary and a $390,390 bonus in 2025, the bonus based wholly on corporate goals.
current state · 2026-04-23written 2026-11-17
C28facthigh confidence
Officers and directors together owned 2.4M shares, 1.3% of the company, in April 2026; one director bought 63,400 shares at $1.59 in November 2025.
current state · 2026-04-15written 2026-11-17
02

Why it wins, and who could beat it

Why customers come back

Nothing protects it yet. If the trial succeeds, GPS would be the first drug approved to keep this leukemia away after a second treatment, and US law would protect it from copies for years as a rare-disease drug made from proteins. Some patents end in 2026, so the rules, not patents, would protect it.

The need is real: only about one patient in three is alive five years after diagnosis, and the one approved drug for keeping the disease away is labelled only for the first remission.

The evidence under this - 4 claims
C18facthigh confidence
The only drug the FDA has approved to keep AML in remission, BMS's oral azacitidine (Onureg), is labelled for a first remission after intensive chemotherapy, not a second.
against this

Doctors already give venetoclax and azacitidine after a second remission off-label, which is part of REGAL's control arm.

current state · 2026-06-12written 2026-11-17
C22facthigh confidence
GPS holds FDA orphan drug and Fast Track designations in AML; as a biologic filed under a licence application it would carry 12 years of US data exclusivity, while some GPS peptide patents expire in 2026 and others in 2033 to 2035.
against this

The patent covering the WT1-A1 peptide and some method-of-use patents expire in 2026, so exclusivity would rest on regulation more than on patents.

current state · 2026-03-19written 2026-11-17
C16facthigh confidence
SEER expects 22,720 new US cases of acute myeloid leukemia and 11,500 deaths in 2026; five-year relative survival was 33.4% for 2016 to 2022.
current state · 2026-04-15written 2026-11-17
C19facthigh confidence
Medicare Part D spent about $129,238 per patient on Onureg in 2024 across 665 patients, $85.9M in all.
against this

Part D figures are gross of rebates and cover only Medicare patients on an oral drug; GPS is an injection billed differently.

historical · 2024written 2026-11-17

The threat

Doctors already keep many patients on the drugs that put them into remission, AbbVie's venetoclax and azacitidine, and send fit patients to a stem cell transplant, the only proven cure. Newer drugs such as Syndax's Revuforj treat relapse in patients with certain gene changes.

The evidence under this - 3 claims
C21facthigh confidence
SELLAS's 10-K names AbbVie's Venclexta, Pfizer's Mylotarg, Daiichi Sankyo's Vanflyta, Rigel's Rezlidhia, Syndax's revumenib and BMS's Vidaza and Onureg as AML competitors, and says no WT1 therapy competes in second-remission maintenance.
current state · 2026-03-19written 2026-11-17
C20facthigh confidence
The FDA has approved Syndax's menin inhibitor Revuforj for relapsed AML with an NPM1 mutation or a KMT2A rearrangement.
against this

It treats relapse in two genetic subtypes; it is not a maintenance drug for every patient in second remission.

current state · 2026-02-04written 2026-11-17
C18facthigh confidence
The only drug the FDA has approved to keep AML in remission, BMS's oral azacitidine (Onureg), is labelled for a first remission after intensive chemotherapy, not a second.
against this

Doctors already give venetoclax and azacitidine after a second remission off-label, which is part of REGAL's control arm.

current state · 2026-06-12written 2026-11-17

The rivals: ABBV, BMY, SNDX, and 1 more that is private, in-house or listed abroad.

Who else does this, rival by rival
TickerRivalWhere it competesHow far alongPriced against it
ABBVAbbVie's venetoclax with azacitidine, continued after remissionPriced against it: One segment onlyTwo cancer drug candidates, GPS and SLS009On saleOne segment only
BMYBMS's oral azacitidine, OnuregPriced against it: One segment onlyTwo cancer drug candidates, GPS and SLS009On saleOne segment only
SNDXSyndax's menin inhibitor RevuforjPriced against it: Different productTwo cancer drug candidates, GPS and SLS009On saleDifferent product
Not listedAllogeneic stem cell transplantPriced against it: Not listedTwo cancer drug candidates, GPS and SLS009On saleNot listed
03

How big it could get

How big this could get

SELLAS counts about 8,750 patients a year in the US, the largest European markets and Japan who reach a second remission. That figure is the company's own arithmetic from older reports, and not all of those patients would be eligible.

For scale, Medicare paid about $129,000 a patient for Bristol Myers Squibb's Onureg in 2024, across 665 patients. At that price, 8,750 patients would be about $1.1B a year before any share of the market is assumed.

The evidence under this - 3 claims
C17management claimmedium confidence
SELLAS counts about 8,750 patients a year in the US, the four largest EU markets and Japan who reach a second remission, from third-party counts of second-line treatment and a 50% remission rate.
against this

The counts are from 2022 reports and the 50% rate is from older salvage regimens; not all those patients are ineligible for transplant, which REGAL requires.

current state · 2026-03-19written 2026-11-17
C16facthigh confidence
SEER expects 22,720 new US cases of acute myeloid leukemia and 11,500 deaths in 2026; five-year relative survival was 33.4% for 2016 to 2022.
current state · 2026-04-15written 2026-11-17
C19facthigh confidence
Medicare Part D spent about $129,238 per patient on Onureg in 2024 across 665 patients, $85.9M in all.
against this

Part D figures are gross of rebates and cover only Medicare patients on an oral drug; GPS is an injection billed differently.

historical · 2024written 2026-11-17
04

The results

What growth costs

With no sales there is nothing to compare costs against. Spending fell in 2025 after the trial finished enrolling, then rose 56% in the first nine months of 2026 as the company prepares to apply for approval.

The evidence under this - 2 claims
C08facthigh confidence
Operations used $22.4M of cash in the nine months to September 2026; the quarter's net loss was $10.1M, with research costs up 67% to $7.0M as the company prepares a licence application.
historical · nine months to 2026-09-30written 2026-11-17
C32facthigh confidence
Net loss narrowed to $26.9M in 2025 from $30.9M in 2024, as research costs fell from $19.1M to $16.0M after REGAL finished enrolling.
historical · 2024 to 2025written 2026-11-17

The last report (12 Nov)

In the quarter to September 2026 SELLAS lost $10.1M, as research spending rose to $7.0M while it prepares to apply for approval. It ended the quarter with $134.7M of cash after warrant holders paid in $85.1M this year, and no debt.

It said the trial result would come in November and that the first SLS009 data in newly diagnosed patients would come by the end of the year.

What it did to the thesisIt changed nothing about the case. The cash covers years of trials at this pace, so the company will not be forced to sell shares before the result, but the quarter held no new evidence on whether GPS works.

The quarter in detail

Earnings per share $-0.05 against $-0.05 expected; $-0.05 as filed, with no adjustments.

The evidence under this - 4 claims
C08facthigh confidence
Operations used $22.4M of cash in the nine months to September 2026; the quarter's net loss was $10.1M, with research costs up 67% to $7.0M as the company prepares a licence application.
historical · nine months to 2026-09-30written 2026-11-17
C07facthigh confidence
Cash and cash equivalents were $134.7M on 30 September 2026, against $71.8M at the end of 2025, with $9.3M of total liabilities and no debt.
current state · 2026-09-30written 2026-11-17
C26management claimhigh confidence
A randomised 80-patient Phase 2 trial of SLS009 in newly diagnosed AML had 40 patients enrolled by 5 November 2026, with preliminary data promised in the fourth quarter of 2026.
against this

The registry lists primary completion at the end of 2026, so data on half the patients may be early.

forwardwritten 2026-11-17
C05management claimhigh confidence
SELLAS says it will report REGAL's topline primary endpoint result in November 2026.
against this

The 28 October release promised the result 'this quarter', which runs to the end of December.

forwardwritten 2026-11-17
What management did with the money

SELLAS has funded itself by selling shares and warrants, the right to buy shares later at a set price. The share count went from 74 million at the end of 2024 to 204 million in November 2026. In July 2026 it lost an arbitration against its Chinese partner. A $150M programme to sell more shares is in place and unused.

Insiders in 2026Q2: 1 purchases and 0 sales, from their Form 4 filings.

The evidence under this - 4 claims
C10facthigh confidence
Shares outstanding rose from 74.0M at the end of 2024 to 153.1M at the end of 2025 and 203.9M on 11 November 2026; $85.1M came in 2026 from 50.4M warrants exercised at an average $1.69.
historical · December 2024 to November 2026written 2026-11-17
C11facthigh confidence
8.1M warrants at $1.41 to $2.00 and 2.7M options were outstanding at 30 September 2026.
current state · 2026-09-30written 2026-11-17
C24facthigh confidence
On 24 July 2026 an arbitrator dismissed SELLAS's claims against 3D Medicines over unpaid milestones and slow development in China, and SELLAS paid about $1.0M of costs.
historical · July 2026written 2026-11-17
C09facthigh confidence
The company says its cash will fund planned operations for at least twelve months, and it has not drawn on a $150M at-the-market share programme set up with TD Cowen in March 2026.
against this

A launch after approval would need a sales force and stock, which the current plan does not include.

current state · 2026-11-12written 2026-11-17
05

The price, and where we disagree

In short. Full: the price pays about nine years of a plausible GPS's sales for a drug whose trial result is not yet out.

Share price
$7.47
close,
Price for each $1 of net worth
11.5
its 6-year normal 5.0

The 80th death in the trial was announced on 28 October 2026, which starts the final count, and the result is promised for November. The shares fell 15% that day and are 53% below their June high, after law firms questioned the timing of the company's statements. More than a quarter of the shares that trade are sold short.

The next test is the result itself: whether patients given GPS lived meaningfully longer than those on standard care.

The evidence under this - 5 claims
C03facthigh confidence
REGAL enrolled 127 patients by March 2024; 60 deaths were reached in December 2024, 72 by 26 December 2025, and the 80th, which triggers the final analysis, on 28 October 2026.
against this

The registry had estimated primary completion in December 2025, so the final count came about ten months later than registered.

historical · March 2024 to October 2026written 2026-11-17
C05management claimhigh confidence
SELLAS says it will report REGAL's topline primary endpoint result in November 2026.
against this

The 28 October release promised the result 'this quarter', which runs to the end of December.

forwardwritten 2026-11-17
C12facthigh confidence
The shares closed at $7.47 on 16 November 2026, 53% below the June 2026 high of $15.88 and up about fourfold over 252 sessions.
current state · 2026-11-16written 2026-11-17
C14facthigh confidence
Short sellers held 57.1M shares, 28.3% of the float, at the 30 October 2026 settlement, 6.7 days of trading.
current state · 2026-10-30written 2026-11-17
C30facthigh confidence
A law firm said in October 2026 that it was investigating claims for investors over the timing of REGAL disclosures; the 10-Q reported no pending or threatened litigation at 30 September 2026.
against this

Such investigations are solicitations for clients; none has become a filed suit.

current state · 2026-11-12written 2026-11-17
The betPriced for success
If it works
0.6×
from today's value, at the stated multiple
If it fails
keep 5%
of today's market value: what the worst case leaves shareholders
How we value it

No fair value: SELLAS has no sales, has never made a profit, and its value turns on one trial result not yet public, so a value built on earnings would rest on a guess; the bet prices it instead.

How we read the multiple

At $7.47 the 204 million shares are worth about $1.5B. Take away the $135M of cash and the price pays about $1.39B for two drugs that are not yet approved.

If GPS is approved and reaches about 1,160 patients a year at Onureg's price, sales would be about $150M a year, so the price is about nine years of those sales. That already assumes success.

Against its own history. It trades far above its usual price against its net worth, because the money raised this year is small beside what buyers now pay for the trial.

The evidence under this - 4 claims
C13inferencehigh confidence
At $7.47 the 203.9M shares are worth about $1,523M, 11.6 times book value of $131.8M, so the price pays about $1.39B above the cash for two unproven drugs.
derivedC12 gives the close, C10 the share count and C07 the cash; book value is the 10-Q's stockholders' equity, nearly all of it cash.
against this

SLS009 has its own value apart from GPS, so not all of the $1.39B is a bet on REGAL.

current state · 2026-11-16written 2026-11-17
C07facthigh confidence
Cash and cash equivalents were $134.7M on 30 September 2026, against $71.8M at the end of 2025, with $9.3M of total liabilities and no debt.
current state · 2026-09-30written 2026-11-17
C31estimatelow confidence
If GPS is approved and treats about 1,160 patients a year at Onureg's Medicare price, revenue would be about $150M, near 13% of the 8,750 patients SELLAS counts and 1.7 times Onureg's 665 Medicare patients.
derivedC19's price per patient against C17's patient count and C19's Onureg patient count; the price GPS would carry is not known.
against this

A maintenance drug that extends survival keeps each patient on treatment longer, which would raise the revenue per patient above one year's price.

forwardwritten 2026-11-17
C12facthigh confidence
The shares closed at $7.47 on 16 November 2026, 53% below the June 2026 high of $15.88 and up about fourfold over 252 sessions.
current state · 2026-11-16written 2026-11-17
Priced against its rivals

None of the listed rivals above sells the same thing to the same buyers as a large part of what it does. A price comparison needs at least two, so the price is judged against its own history instead.

Also checked and set aside: Curis (a substitute, not the same product).

Private or foreign rivals that cannot be priced: Delta-Fly Pharma, Inc., AROG Pharmaceuticals, Inc., Cothera Bioscience.

The bet: what it pays if it works

If the trial works and GPS is approved, a reasonable result is about 1,160 patients a year, nearly twice Onureg's Medicare patients, and about $150M of sales. At six times sales that is worth about $900M, less than today's market value, so even success pays little from here.

If the trial fails, holders keep the cash left after a couple of years of SLS009 trials, about a twentieth of today's value. The bet is priced for success.

Revenue in two to three yearsPatients treated for a year neededAt the stated multiple
$50.00Mabout 387 at 100% kept0.2×
$150.00M (the big win)about 1.2K at 100% kept0.6×
$357.60Mabout 2.8K at 100% kept1.4×

To pay 2× (a Fair bet) it would need about $507.61M of revenue (about 3.9K patients treated for a year); to pay 5× (a Cheap bet), about $1.27B of revenue (about 9.8K patients treated for a year), at the same multiple.

The steps it has to take

  • Done REGAL enrolment completed
  • Done Committee lets REGAL continue at the 60-death interim
  • Done 80th death reached, final analysis triggered
  • In progress Positive REGAL topline survival result due 2026-12
  • Not started Licence application filed with the FDA due 2027-12
  • Not started FDA approval and first sales due 2028-12
The detail behind the label
Rating
Expensive
the big win's payoff against the 2× and 5× lines
Cheap bet at about
$0.88
88% below the price (close, )
The evidence under this - 4 claims
C31estimatelow confidence
If GPS is approved and treats about 1,160 patients a year at Onureg's Medicare price, revenue would be about $150M, near 13% of the 8,750 patients SELLAS counts and 1.7 times Onureg's 665 Medicare patients.
derivedC19's price per patient against C17's patient count and C19's Onureg patient count; the price GPS would carry is not known.
against this

A maintenance drug that extends survival keeps each patient on treatment longer, which would raise the revenue per patient above one year's price.

forwardwritten 2026-11-17
C19facthigh confidence
Medicare Part D spent about $129,238 per patient on Onureg in 2024 across 665 patients, $85.9M in all.
against this

Part D figures are gross of rebates and cover only Medicare patients on an oral drug; GPS is an injection billed differently.

historical · 2024written 2026-11-17
C07facthigh confidence
Cash and cash equivalents were $134.7M on 30 September 2026, against $71.8M at the end of 2025, with $9.3M of total liabilities and no debt.
current state · 2026-09-30written 2026-11-17
C08facthigh confidence
Operations used $22.4M of cash in the nine months to September 2026; the quarter's net loss was $10.1M, with research costs up 67% to $7.0M as the company prepares a licence application.
historical · nine months to 2026-09-30written 2026-11-17

Where we disagree with the market

The market believes

The trial will probably work, and the slow deaths show it.

We believe

It may work, but the evidence is thin and success is already in the price.

Every analyst covering it rates it a buy, and many holders read the slow pace of deaths in the trial as a sign that GPS patients are living longer.

We cannot read it that way: the deaths are counted across both groups together, and the earlier evidence is ten patients compared with others who were not chosen at random. The trial could well succeed, but the price already pays for that.

What analysts say, and the evidence
Analysts positive
100%
of 2, 1 Nov
Four months earlier
100%
of 2, 1 Jul
The evidence under this - 5 claims
C15facthigh confidence
Five analysts rate the shares a buy and none a sell; one publishes estimates, with sales of $122.0M in 2028, $357.6M in 2029 and $630.3M in 2030.
against this

One analyst is no consensus, and FMP's dated series counts only two analysts against five in the snapshot.

current state · 2026-11-16written 2026-11-17
C04facthigh confidence
In January 2025 the independent data monitoring committee reviewed REGAL at 60 deaths and recommended it continue without modification.
against this

A recommendation to continue only means the trial did not cross the futility or efficacy boundaries; it is not evidence that GPS works.

historical · January 2025written 2026-11-17
C06facthigh confidence
GPS's case rests on a 10-patient Phase 2 trial at Moffitt in second remission: median survival of 21.0 months against 5.4 months in 15 patients treated at the same centre but not randomised.
against this

The comparison was not randomised and the GPS group was ten patients, so patients well enough to take a vaccine could simply have been healthier.

historical · Phase 2, final data at 30.8 months' follow-upwritten 2026-11-17
C03facthigh confidence
REGAL enrolled 127 patients by March 2024; 60 deaths were reached in December 2024, 72 by 26 December 2025, and the 80th, which triggers the final analysis, on 28 October 2026.
against this

The registry had estimated primary completion in December 2025, so the final count came about ten months later than registered.

historical · March 2024 to October 2026written 2026-11-17
C13inferencehigh confidence
At $7.47 the 203.9M shares are worth about $1,523M, 11.6 times book value of $131.8M, so the price pays about $1.39B above the cash for two unproven drugs.
derivedC12 gives the close, C10 the share count and C07 the cash; book value is the 10-Q's stockholders' equity, nearly all of it cash.
against this

SLS009 has its own value apart from GPS, so not all of the $1.39B is a bet on REGAL.

current state · 2026-11-16written 2026-11-17
06

What could go wrong, and how we would know

The risks

  • One result decides it If the trial misses, most of the value goes, leaving cash and the second drug.
  • Thin earlier evidence The case rests on ten patients and studies with no fair comparison group.
  • Open-label trial Doctors and patients knew who got GPS, which regulators may weigh against a small benefit.
  • More shares Launching a drug costs far more than the cash, so new shares are likely even after success.
  • Delays The final count came about ten months later than the trial registry had estimated.
The evidence under this - 5 claims
C02facthigh confidence
REGAL is a 1:1 randomised, open-label Phase 3 trial of GPS against investigators' choice of best available treatment in AML patients in second complete remission who cannot have a transplant; the primary endpoint is overall survival.
current state · 2026-10-28written 2026-11-17
C06facthigh confidence
GPS's case rests on a 10-patient Phase 2 trial at Moffitt in second remission: median survival of 21.0 months against 5.4 months in 15 patients treated at the same centre but not randomised.
against this

The comparison was not randomised and the GPS group was ten patients, so patients well enough to take a vaccine could simply have been healthier.

historical · Phase 2, final data at 30.8 months' follow-upwritten 2026-11-17
C10facthigh confidence
Shares outstanding rose from 74.0M at the end of 2024 to 153.1M at the end of 2025 and 203.9M on 11 November 2026; $85.1M came in 2026 from 50.4M warrants exercised at an average $1.69.
historical · December 2024 to November 2026written 2026-11-17
C09facthigh confidence
The company says its cash will fund planned operations for at least twelve months, and it has not drawn on a $150M at-the-market share programme set up with TD Cowen in March 2026.
against this

A launch after approval would need a sales force and stock, which the current plan does not include.

current state · 2026-11-12written 2026-11-17
C03facthigh confidence
REGAL enrolled 127 patients by March 2024; 60 deaths were reached in December 2024, 72 by 26 December 2025, and the 80th, which triggers the final analysis, on 28 October 2026.
against this

The registry had estimated primary completion in December 2025, so the final count came about ten months later than registered.

historical · March 2024 to October 2026written 2026-11-17
What we still do not know
  • What survival gain the trial was designed to show, and how likely it was to show it.
  • Whether insurers would pay for GPS like a cancer drug or like a cheaper vaccine.
  • Whether SLS009 works well enough in newly diagnosed patients to carry the company if GPS fails.
The evidence under this - 3 claims
C02facthigh confidence
REGAL is a 1:1 randomised, open-label Phase 3 trial of GPS against investigators' choice of best available treatment in AML patients in second complete remission who cannot have a transplant; the primary endpoint is overall survival.
current state · 2026-10-28written 2026-11-17
C19facthigh confidence
Medicare Part D spent about $129,238 per patient on Onureg in 2024 across 665 patients, $85.9M in all.
against this

Part D figures are gross of rebates and cover only Medicare patients on an oral drug; GPS is an injection billed differently.

historical · 2024written 2026-11-17
C26management claimhigh confidence
A randomised 80-patient Phase 2 trial of SLS009 in newly diagnosed AML had 40 patients enrolled by 5 November 2026, with preliminary data promised in the fourth quarter of 2026.
against this

The registry lists primary completion at the end of 2026, so data on half the patients may be early.

forwardwritten 2026-11-17

What would change our view

  1. Neutral→AttractiveThe trial works

    It needs all of:

    • ○The trial shows patients on GPS live longer, by a margin unlikely to be chance.watched as it happens
    • ○SELLAS applies for approval with the FDA's agreement.watched as it happens
  2. Neutral→UnattractiveThe trial fails

    It needs:

    • ○The trial misses its survival goal.watched as it happens
  3. Neutral→AttractiveA price that pays little for the drugs

    It needs:

    • ○Before the result, market value falls to five times book value, what it owns minus what it owes.about $3.22 today, 57% below the last close
We would also be wrong if
  • The FDA will not accept an application based on an open-label trial.
  • SELLAS sells more than 40 million new shares before any approval.
  • SLS009 beats standard drugs in its randomised trial in newly diagnosed patients.

What is coming

  • 30 November 2026 REGAL topline primary endpoint result: Whether GPS extends survival in second remission with statistical significance: the whole case.
Every dated event ahead
  • 30 November 2026 REGAL topline primary endpoint result: Whether GPS extends survival in second remission with statistical significance: the whole case.
  • 31 December 2026 SLS009 relapsed AML data at ASH, and first-line preliminary data: Whether the second drug works where venetoclax fails, the fallback if REGAL disappoints.
  • 25 March 2027 FY2026 annual report: Cash left, the plan for a licence application and how much new stock was sold.
Since we wrote this
Written
17 Nov
Price the thesis read
$7.47
16 Nov
  • 17 NovThesis writtenNeutral, low convictionWritten days before the REGAL topline result, with the shares at $7.47 after a 53% fall from June.

Sources 13

Where this came from

Sources - 13

Every claim above cites one of these, or states the reasoning that derived it. The quote is frozen at the date it was read: a link can rot, and an agent fetch returns a reading of a page rather than the page. Backs counts the whole claim ledger, so it can name a claim this page does not surface.

  1. S01primarycompany filing2026-03-19
    the two drug candidates, the REGAL design and event history, the licences with MSK, GenFleet and 3D Medicines, the patents, the named competitors, the patient counts, the 2025 and 2024 statements and the share count
    backsC01C02C03C04C06C10C17C18C21C22C23C29C32
  2. S02primarycompany filing2026-11-12
    cash, costs, cash used, the warrant exercises and the unused at-the-market programme, warrants and options outstanding, the lost arbitration, the SLS009 data and enrolment, and the share count on 11 November 2026
    backsC01C07C08C09C10C11C24C25C26C30
  3. S03primarycompany filing2026-11-12
    the quarter's costs and loss, cash of $134.7M, and the promise of REGAL topline results in November 2026 and first-line SLS009 data in the fourth quarter
    backsC05C07C08C25C26
  4. S04primarycompany filing2026-03-19
    the full-year 2025 results and the plan for 2026 announced beside the annual report
    read, but no claim rests on it
  5. S05primarycompany filing2026-04-23
    the officers and directors, what they own, what the chief executive is paid and what the bonus is paid on
    backsC27C28
  6. S06primarycompany release2026-10-28
    the 80th death in REGAL on 28 October 2026, which starts the final analysis
    has reached the pre-specified 80 th event (number of deaths), triggering the final analysis of the study
    backsC03C05
  7. S07secondaryvendor data2026-11-16
    Research pack, frozen beside this thesis
    content/SLS/research-pack.json
    the close, the price history, short interest, the analyst panel and the one analyst's estimates, and the insider roster
    backsC12C14C15C28C30
  8. S08primaryregulator2025-10-01
    REGAL's design as registered: open-label, 127 patients actually enrolled, survival as the primary endpoint, and a control arm of investigators' choice that includes observation
    Open-label, multicenter, randomized, parallel group study
    backsC02C03
  9. S09primarygovernment data2026-04-15
    new US AML cases and deaths expected in 2026, and five-year relative survival of 33.4% for 2016 to 2022
    In 2026, it is estimated that there will be 22,720 new cases of acute myeloid leukemia ... an estimated 11,500 people will die of this disease ... 5-year relative survival 33.4% ... SEER 21 (Excluding IL) 2016-2022
    backsC16
  10. S10primaryregulator2026-06-12
    that the one approved drug for keeping AML in remission is labelled for a first remission only
    indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission
    backsC18
  11. S11primaryregulator2026-02-04
    that Syndax's menin inhibitor is approved for relapsed AML with an NPM1 mutation or a KMT2A rearrangement
    the treatment of relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1
    backsC20
  12. S12primarygovernment data2026-06-01
    CMS, Medicare Part D Spending by Drug, data year 2024: Onureg Centers for Medicare & Medicaid Services
    Medicare Part D spending on Onureg in 2024: 665 patients and about $129,238 per patient
    Brnd_Name Onureg Tot_Spndng_2024 85943002.48 Tot_Benes_2024 665 Avg_Spnd_Per_Bene_2024 129237.59771
    backsC19
  13. S13primaryregulator2026-09-03
    the SLS009 study's registered enrolment of 160 and an estimated primary completion at the end of 2026
    Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies
    backsC26
Rendered from content/SLS/thesis.json · thesis reviewed 2026-11-17. This page explains a company; it does not say what to pay, when to buy or how much.